Published in J Virol on December 01, 1992
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A (1994) 4.07
Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol (2009) 3.67
Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58
Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog (2006) 3.57
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A (2009) 3.47
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol (1993) 2.63
CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol (1996) 2.61
Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1. Mol Cell Biol (1995) 2.55
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol (1995) 2.48
HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem (2009) 2.42
Host restriction factors blocking retroviral replication. Annu Rev Genet (2008) 2.41
CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol (1995) 2.22
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol (1995) 2.17
Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol (1994) 2.17
Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12
The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology (2009) 2.11
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol (1995) 2.08
The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol (1996) 2.01
CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med (2002) 2.00
The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. Physiol Rev (2012) 1.95
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol (2013) 1.93
Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc Natl Acad Sci U S A (1999) 1.87
HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology (2010) 1.87
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog (2010) 1.85
Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol (2002) 1.85
Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol (2001) 1.80
Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol (2006) 1.77
Nef from primary isolates of human immunodeficiency virus type 1 suppresses surface CD4 expression in human and mouse T cells. J Virol (1993) 1.77
Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe (2010) 1.74
The ubiquitin system, disease, and drug discovery. BMC Biochem (2008) 1.73
Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog (2010) 1.66
Retracted Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. Nat Med (2008) 1.63
Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J Virol (1993) 1.63
Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood (2010) 1.62
Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest (1998) 1.61
The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by human immunodeficiency virus type 1 Nef. J Virol (1994) 1.60
Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol (2010) 1.60
The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med (1997) 1.55
Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci (2002) 1.54
Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol (1995) 1.50
HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog (2008) 1.50
Human immunodeficiency virus type 1 Nef induces accumulation of CD4 in early endosomes. J Virol (1995) 1.49
Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology (2007) 1.48
Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef. J Virol (1993) 1.48
Molecular biology of the human immunodeficiency virus accessory proteins. J Virol (1994) 1.44
The envelope glycoprotein of an amphotropic murine retrovirus binds specifically to the cellular receptor/phosphate transporter of susceptible species. J Virol (1995) 1.43
The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors. J Exp Med (2001) 1.38
Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol (2011) 1.35
Gibbon ape leukemia virus and the amphotropic murine leukemia virus 4070A exhibit an unusual interference pattern on E36 Chinese hamster cells. J Virol (1993) 1.35
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
The majority of cells are superinfected in a cloned cell line that produces high levels of human immunodeficiency virus type 1 strain MN. J Virol (1995) 1.34
Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. J Virol (1998) 1.32
The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol (2014) 1.32
Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol (1999) 1.31
CD4-CCR5 interaction in intracellular compartments contributes to receptor expression at the cell surface. Blood (2008) 1.31
Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog (2010) 1.29
Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology (2010) 1.28
Sequences present in the cytoplasmic domain of CD4 are necessary and sufficient to confer sensitivity to the human immunodeficiency virus type 1 Vpu protein. J Virol (1994) 1.27
Degradation of tobacco mosaic virus movement protein by the 26S proteasome. J Virol (2000) 1.27
Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology (2010) 1.26
CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A (2015) 1.25
BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog (2009) 1.24
The dual-function hamster receptor for amphotropic murine leukemia virus (MuLV), 10A1 MuLV, and gibbon ape leukemia virus is a phosphate symporter. J Virol (1995) 1.24
Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: differentiation from a CD4-positive precursor allows productive infection. J Virol (1997) 1.24
BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology (2011) 1.20
CD4 cell surface downregulation in HIV-1 Nef transgenic mice is a consequence of intracellular sequestration. EMBO J (1993) 1.17
Neuronal cell surface molecules mediate specific binding to rabies virus glycoprotein expressed by a recombinant baculovirus on the surfaces of lepidopteran cells. J Virol (1998) 1.14
Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol (2012) 1.14
HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis. J Virol (2014) 1.14
Vpr and Vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo. J Virol (2004) 1.12
Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4. J Virol (1996) 1.10
HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med (2010) 1.09
Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression. J Virol (1995) 1.09
Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J Virol (2006) 1.08
A genetic approach to inactivating chemokine receptors using a modified viral protein. Nat Biotechnol (2003) 1.07
Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence. Cell Logist (2011) 1.06
Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J Virol (2010) 1.06
Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol (2011) 1.05
Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1 beta. Clin Exp Immunol (1995) 1.04
Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J Virol (2007) 1.03
Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu. J Virol (2011) 1.01
Human immunodeficiency virus type 1 Nef-induced CD4 cell surface downregulation is inhibited by ikarugamycin. J Virol (2001) 1.01
Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals. J Virol (2005) 1.01
HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins. J Virol (2014) 0.99
Structural studies of the HIV-1 accessory protein Vpu in langmuir monolayers: synchrotron X-ray reflectivity. Biophys J (2001) 0.98
Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing. J Virol (1999) 0.98
Cytopathic mechanisms of HIV-1. Virol J (2007) 0.97
Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M. J Virol (2013) 0.95
Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule. J Virol (1997) 0.95
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 20.55
Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell (1989) 13.41
Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell (1987) 11.56
pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell (1987) 9.29
Influenza virus M2 protein has ion channel activity. Cell (1992) 8.52
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature (1991) 6.79
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem (1986) 6.03
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science (1986) 4.79
Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology (1991) 4.77
Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell (1988) 4.42
Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J (1988) 3.98
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol (1990) 2.96
Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J (1990) 2.93
Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly. J Cell Biol (1989) 2.65
Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. J Virol (1990) 2.21
Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology (1991) 2.05
Characterization of human immunodeficiency virus type 2 envelope glycoproteins: dimerization of the glycoprotein precursor during processing. J Virol (1989) 1.93
Downregulation of cell surface molecules during noncytopathic infection of T cells with human immunodeficiency virus. J Virol (1987) 1.85
Depletion of the surface CD4 molecule by the envelope protein of human immunodeficiency virus expressed in a human CD4+ monocytoid cell line. J Virol (1989) 1.73
Phosphorylation-dependent down-modulation of CD4 requires a specific structure within the cytoplasmic domain of CD4. J Biol Chem (1991) 1.62
Inhibition of gp160 and CD4 maturation in U937 cells after both defective and productive infections by human immunodeficiency virus type 1. J Virol (1991) 1.50
Depletion of cellular calcium accelerates protein degradation in the endoplasmic reticulum. J Biol Chem (1991) 1.49
Phosphorylation and degradation of HMG CoA reductase. Adv Enzyme Regul (1989) 0.92
The ubiquitin-mediated proteolytic pathway: enzymology and mechanisms of recognition of the proteolytic substrates. Semin Cell Biol (1990) 0.90
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Quantitation of Simian virus 40 sequences in African green monkey, mouse and virus-transformed cell genomes. J Mol Biol (1971) 7.10
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell (1998) 5.89
A rapid method for detecting and mapping homology between heterologous DNAs. Evaluation of polyomavirus genomes. J Biol Chem (1979) 5.32
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
A map of simian virus 40 transcription sites expressed in productively infected cells. J Mol Biol (1973) 5.02
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins. J Virol (1986) 3.89
Nucleotide sequence and genome organization of foot-and-mouth disease virus. Nucleic Acids Res (1984) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Patterns of Simian Virus 40 DNA transcription after acute infection of permissive and nonpermissive cells. Proc Natl Acad Sci U S A (1972) 3.65
Genetic recombination of human immunodeficiency virus. J Virol (1989) 3.61
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol (1989) 3.36
SV40 gene activity during lytic infection and in a series of SV40 transformed mouse cells. Proc Natl Acad Sci U S A (1969) 3.30
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A (2006) 3.26
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 3.25
Identification of ecotropic proviral sequences in inbred mouse strains with a cloned subgenomic DNA fragment. Proc Natl Acad Sci U S A (1980) 3.19
Molecular cloning of polyoma virus DNA in Escherichia coli: lambda phage vector system. Science (1979) 3.17
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
Envelope and long terminal repeat sequences of a cloned infectious NZB xenotropic murine leukemia virus. J Virol (1985) 3.06
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol (1979) 3.04
Characterization of murine leukaemia virus-specific DNA present in normal mouse cells. Nat New Biol (1973) 2.98
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
A second protease of foot-and-mouth disease virus. J Virol (1986) 2.87
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem (1995) 2.70
Common methionine-tryptic peptides near the amino-terminal end of primate papovavirus tumor antigens. Proc Natl Acad Sci U S A (1978) 2.63
Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol (1993) 2.63
Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis (1997) 2.60
Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol (1989) 2.60
Structure of the FMDV translation initiation site and of the structural proteins. Nucleic Acids Res (1983) 2.58
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med (1999) 2.53
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol (1995) 2.48
Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett (1996) 2.43
Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol (1995) 2.43
CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38
Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol (1985) 2.36
Characterization of polyoma viral DNA sequences in polyoma-induced hamster tumor cell lines. J Biol Chem (1980) 2.33
Thermal stabilities and species specificities of reannealed animal deoxyribonucleic acids. Biochemistry (1966) 2.32
Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation. J Virol (1991) 2.30
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
Transcription of novel open reading frames of AIDS retrovirus during infection of lymphocytes. Science (1985) 2.28
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
Identification and cloning of endogenous retroviral sequences present in human DNA. Proc Natl Acad Sci U S A (1981) 2.26
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Physical map of the BK virus genome. J Virol (1975) 2.18
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
Endogenous murine leukemia proviral long terminal repeats contain a unique 190-base-pair insert. Proc Natl Acad Sci U S A (1983) 2.10
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Cloning and characterization of an envelope-specific probe from xenotropic murine leukemia proviral DNA. J Virol (1982) 2.09
Specific hybridization probes demonstrate fewer xenotropic than mink cell focus-forming murine leukemia virus env-related sequences in DNAs from inbred laboratory mice. J Virol (1986) 2.08
Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology (1991) 2.05
Patterns of simian virus 40 deoxyribonucleic acid transcription. II. In transformed cells. J Virol (1973) 2.04
Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol (1998) 2.01
mRNA transcripts related to full-length endogenous retroviral DNA in human cells. Nature (1984) 1.94
The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif. J Mol Biol (1994) 1.93
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J Virol (1994) 1.92
Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol (1998) 1.90